Atea Pharmaceuticals Inc (NASDAQ: AVIR) is 34.43% higher on its value in year-to-date trading and has touched a low of $2.77 and a high of $5.19 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AVIR stock was last observed hovering at around $3.95 in the last trading session, with the day’s gains setting it 0.15%.
Currently trading at $4.10, the stock is -0.18% and 2.86% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.05 million and changing 3.80% at the moment leaves the stock 17.62% off its SMA200. AVIR registered 19.88% gain for a year compared to 6-month gain of 28.93%. The firm has a 200-day simple moving average (SMA200) of $1.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.61% loss in the last 1 month and extending the period to 3 months gives it a 30.99%, and is 6.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.18% over the week and 5.14% over the month.
Atea Pharmaceuticals Inc (AVIR) has around 75 employees, a market worth around $345.06M and $0.00M in sales. Distance from 52-week low is 48.28% and -21.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.42%).
Atea Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.61.The EPS is expected to shrink by -41.82% this year
151 institutions hold shares in Atea Pharmaceuticals Inc (AVIR), with institutional investors hold 74.47% of the company’s shares. The shares outstanding are 83.44M, and float is at 73.79M with Short Float at 2.23%. Institutions hold 67.42% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 8.5 million shares valued at $31.78 million. The investor’s holdings represent 10.19% of the AVIR Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 7.71 million shares valued at $28.83 million to account for 9.24% of the shares outstanding. The other top investors are EcoR1 Capital, LLC which holds 7.0 million shares representing 8.39% and valued at over $26.16 million, while Vanguard Group Inc holds 5.42% of the shares totaling 4.52 million with a market value of $16.9 million.
Atea Pharmaceuticals Inc (AVIR) Insider Activity
The most recent transaction is an insider sale by Sommadossi Jean-Pierre, the company’s President, CEO, and Chairman. SEC filings show that Sommadossi Jean-Pierre sold 56,910 shares of the company’s common stock on Feb 01 ’24 at a price of $3.85 per share for a total of $0.22 million. Following the sale, the insider now owns 0.12 million shares.
Atea Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 01 ’24 that Horga Maria Arantxa (Chief Medical Officer) sold a total of 15,870 shares of the company’s common stock. The trade occurred on Feb 01 ’24 and was made at $3.84 per share for $60963.0. Following the transaction, the insider now directly holds 25664.0 shares of the AVIR stock.
Still, SEC filings show that on Feb 01 ’24, Corcoran Andrea () disposed off 15,843 shares at an average price of $3.84 for $60915.0. The insider now directly holds 670,208 shares of Atea Pharmaceuticals Inc (AVIR).
